A Phase 1 interventional study of venetoclax and azacitidine in Myelodysplastic Syndromes (MDS), sponsored by AbbVie. Completed at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-09.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing venetoclax in Myelodysplastic Syndromes — 17 open to participants now, 27 under way, 2 of them phase 3. venetoclax · Myelodysplastic Syndromes.
Among the 40 studies testing venetoclax in Myelodysplastic Syndromes, this one is the 17th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 1, and was the 5th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →17 of the 40 studies testing venetoclax in Myelodysplastic Syndromes are open now, in 6 countries. Recruiting first, the newest first:
OHSU Knight Cancer Institute · Sites in United States
Ages 18–65
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 12–60
University of Alabama at Birmingham · Sites in United States
Ages 18–75
Beijing 302 Hospital · Sites in China
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 27 · Phase 3 2
First in 2010; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 58 across the 40 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 40 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 4 studies filed under Myelodysplastic Syndromes — fewer than ten, so there is no comparison to draw.
7 of the studies testing venetoclax in Myelodysplastic Syndromes that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04401748Phase 3AbbVieStudy Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | 2027-07 |
| NCT07044544University of Alabama at BirminghamTrial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | 2026-12 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
| NCT05986240Montefiore Medical CenterDanvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML | 2027-06 |
| NCT07183878First Affiliated Hospital of Zhejiang UniversityVenetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) | 2027-08-20 |
Add all 7 to your calendar (.ics) → With an account.
Among the 40 studies testing venetoclax in Myelodysplastic Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject enrolled in venetoclax monotherapy must have documented failure of prior therapy with a hypomethylating agent (HMA). HMA-failure is defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: venetoclax
Drug: venetoclax · Drug: azacitidine
Drug: venetoclax · Drug: azacitidine
Tablet
Also known as: ABT-199, GDC-0199
Powder for injection, subcutaneously or intravenous
Also known as: Vidaza
AUCt for azacitidine
Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for azacitidine
Time frame: Up to 32 days
Clearance (CL) for azacitidine
Time frame: Up to 32 days
Cmax for azacitidine
Maximum plasma concentration (Cmax) of azacitidine
Time frame: Up to 32 days
Tmax for venetoclax
Time to Cmax (peak time, Tmax) for venetoclax
Time frame: Up to 32 days
Recommended Phase 2 Dose (RPTD) and dosing schedules of venetoclax as monotherapy and in combination with azacitidine
Time frame: Measured from Day 1 until day 28 per dose level.
AUC[0 to infinity] for azacitidine
Area under the plasma concentration-time curve from Time 0 to infinite time.
Time frame: Up to 32 days
Tmax for azacitidine
Time to Cmax (peak time, Tmax) for azacitidine
Time frame: Up to 32 days
AUC [0-24] for venetoclax
AUC over a 24-hour dose interval (AUC\[0-24\]) for venetoclax
Time frame: Up to 32 days
AUCt for venetoclax
Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for venetoclax
Time frame: Up to 32 days
Cmax of venetoclax
Maximum plasma concentration (Cmax) of venetoclax
Time frame: Up to 32 days
Half-life (t[1/2]) for azacitidine
Terminal elimination half-life (t\[1/2\]) for azacitidine
Time frame: Up to 32 days
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: Up to Maximum of 24 months
Event-Free Survival (EFS)
Time frame: Measured from the date of the first dose of study drug to date of earliest disease progression, death, or initiation of new non-protocol-specified anti-MDS therapy without documented progression, and for up to 5 years after the last subject is enrolled.
Overall Survival (OS)
Time frame: Measured from the date of first dose of study drug to the date of death, and for up to 5 years after the last subject is enrolled.
Rate of Modified Overall Response (mORR)
Proportion of participants with a mORR using best outcome will be calculated.
Time frame: Measured from Cycle 1 Day 1 (C1D1) as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Time to next treatment (TTNT)
Time frame: Measured from first dose of study drug to start of new non-protocol specified MDS therapy, and for up to 5 years after the last subject is enrolled.
Duration of mORR
Defined as the number of days from the date of first response (CR, mCR or PR) to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier..
Time frame: Measured from the date of first response (CR, mCR or PR) to the earliest documentation of progressive disease (PD), and for an anticipated maximum duration of 24 months.
Rate of platelet (PLT) transfusion independence
Proportion of participants who become platelet transfusion-independent
Time frame: Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Time to Transformation acute myeloid leukemia (AML)
Defined as blast count greater than or equal to 20% in either peripheral blood or bone marrow.
Time frame: Measured from the date of first dose of study drug to the date of documented AML transformation for an anticipated maximum duration of 24 months.
Progression-Free Survival (PFS)
Time frame: Measured from the date of the first dose of study drug to the date of earliest disease progression or death, and for an anticipated maximum duration of 24 months.
Overall Response Rate (ORR)
ORR (equals the sum of rates of complete remission \[CR\] + marrow complete remission (mCR) + partial remission \[PR\]) of venetoclax as a single-agent and in combination with azacitidine.
Time frame: Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Complete Remission (CR) Rate
Proportion of subjects who achieved a complete remission.
Time frame: Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Rate of red blood cell (RBC) transfusion independence
Proportion of red blood cell (RBC) transfusion independence.
Time frame: Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Duration of Complete Response (CR)
Duration of CR will be defined as the number of days from the date of first response CR to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier.
Time frame: Measured from date of first response (CR) to the to the earliest documentation of progressive disease or death of any cause, and for an anticipated maximum duration of 24 months.
Rate of Hematologic Improvement (HI)
Proportion of participants with HI (erythroid/platelet/neutrophil responses)
Time frame: Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Rate of marrow complete remission (mCR)
Proportion of participants with marrow complete remission with or without hematological improvement.
Time frame: Measured from Cycle 1 Day 1 (C1D1) as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.
Duration of ORR
Duration of response (ORR) will be defined as the number of days from the date of first response (CR or PR) to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier.
Time frame: Measured from the date of first response (CR or PR) to the earliest documentation of progressive disease or death of any cause, and for an anticipated maximum duration of 24 months.
Plan to share: No
Ran from Mar 2017 to primary completion in Apr 2023, 72 months.
Of 84 industry-sponsored phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 72 months is above that.
Counting every sponsor, half of 220 studies reached it within 52 months; a quarter within 31 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Venetoclax · Azacitidine